ADVISORY, Aug. 21, 2007 (PRIME NEWSWIRE) --
What: Candace Kendle, PharmD, Chairman and Chief Executive Officer of Kendle (KNDL), will preside over the opening bell in celebration of the company's 10-year listing anniversary on NASDAQ. Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio When: Wednesday, August 22, 2007 at 9:30 a.m. ET Contacts: Lori Preuit Dorer 513.345.1685; dorer.lorip@kendle.com Bill Wherle 513.763.1442; wherle.williaml@kendle.com NASDAQ MarketSite: Jolene Libretto; 646.441.5220; mobile - 347.219.9539 Jolene.Libretto@NASDAQ.com
Feed Information:
The opening bell is available from 9:20 a.m. to 9:35 a.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Jolene Libretto at (646) 441-5220.
Radio Feed:
An audio transmission of the opening bell is also available from 9:20 a.m. to 9:35 a.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can be found on Waterfront fiber 1623 as well.
Webcast:
A live webcast of the NASDAQ Opening Bell will be available at: http://www.nasdaq.com/reference/marketsite_about.stm.
Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About Kendle (KNDL):
Headquartered in Cincinnati, Ohio, Kendle International Inc. (Nasdaq:KNDL) is among the world's leading global clinical research organizations and is the fourth-largest provider of Phase II-IV clinical development services worldwide. We deliver innovative and robust clinical development solutions -- from first-in-human studies through market launch and surveillance -- to help the world's biopharmaceutical companies maximize product life cycles and grow market share.
Our global clinical development business is focused on five regions -- North America, Europe, Asia/Pacific, Latin America and Africa -- to meet customer needs. With the expertise of our more than 3,000 associates worldwide, Kendle has conducted clinical trials and provided regulatory and pharmacovigilance services in more than 80 countries. The company was named the "Top CRO to Work With" in the Thomson CenterWatch 2007 Survey of U.S. Investigative Sites.
Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the company's Web site at www.kendle.com.